Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Assertio Therapeutics, Inc.
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
20 mars 2025 09h10 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present...
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
12 mars 2025 16h05 HE
|
Assertio Holdings, Inc.
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow...
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
05 mars 2025 16h05 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 janv. 2025 16h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
17 déc. 2024 08h30 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
13 déc. 2024 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO
12 déc. 2024 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Assertio Reports Third Quarter 2024 Financial Results
11 nov. 2024 16h02 HE
|
Assertio Holdings, Inc.
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 ...
Assertio Provides Response to Letter from Short-seller
11 nov. 2024 07h30 HE
|
Assertio Holdings, Inc.
Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense Company Considering...
Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024
30 oct. 2024 08h00 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...